| 1.88 0 (0%) | 05-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.25  |
1-year : | 2.31 |
| Resists | First : | 1.92 |
Second : | 1.98 |
| Pivot price | 1.91 |
|||
| Supports | First : | 1.84 |
Second : | 1.53 |
| MAs | MA(5) : | 1.89 |
MA(20) : | 1.9 |
| MA(100) : | 1.33 |
MA(250) : | 2.31 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 3 |
D(3) : | 21.5 |
| RSI | RSI(14): 59.5 | |||
| 52-week | High : | 5.48 | Low : | 0.57 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ JNCE ] has closed above bottom band by 10.1%. Bollinger Bands are 81.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.88 - 1.89 | 1.89 - 1.9 |
| Low: | 1.85 - 1.87 | 1.87 - 1.88 |
| Close: | 1.86 - 1.88 | 1.88 - 1.9 |
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Wed, 03 May 2023
Jounce Therapeutics Announces Closing of Tender Offer - GlobeNewswire
Tue, 18 Apr 2023
Jounce Acquisition: Exploring Whether It Is Worth It To Pay Up For CVR Value (NASDAQ:JNCE) - Seeking Alpha
Mon, 27 Mar 2023
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share ... - GlobeNewswire
Tue, 14 Mar 2023
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences - GlobeNewswire
Thu, 23 Feb 2023
Redx and Jounce Announce Recommended Business Combination - GlobeNewswire
Thu, 23 Feb 2023
Why Jounce Therapeutics Shares Are Trading Higher Today - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 15.9 (%) |
| Held by Institutions | 85.3 (%) |
| Shares Short | 2,020 (K) |
| Shares Short P.Month | 3,180 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.53 |
| Profit Margin | -62.1 % |
| Operating Margin | -63.8 % |
| Return on Assets (ttm) | -14.1 % |
| Return on Equity (ttm) | -25.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.51 |
| Sales Per Share | 1.55 |
| EBITDA (p.s.) | -0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.96 |
| PEG Ratio | 0 |
| Price to Book value | 0.53 |
| Price to Sales | 1.2 |
| Price to Cash Flow | -3.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|